G. Singh et al., GASTROINTESTINAL-TRACT COMPLICATIONS OF NONSTEROIDAL ANTIINFLAMMATORYDRUG-TREATMENT IN RHEUMATOID-ARTHRITIS - A PROSPECTIVE OBSERVATIONAL COHORT STUDY, Archives of internal medicine, 156(14), 1996, pp. 1530-1536
Background: Gastrointestinal tract (GI) complications associated with
nonsteroidal anti-inflammatory drug (NSAID) use are the most common se
rious adverse drug reactions in the United States. Nonsteroidal antiin
flammatory drugs cause both minor GI side effects such as abdominal pa
in and vomiting and serious GI events such as ulcers and bleeding. Thi
s study evaluates the event rates for all NSAID-induced GI complicatio
ns in patients with rheumatoid arthritis, describes the time course of
these events, and evaluates the role of prophylactic therapy with ant
acids and H-2 receptor antagonists. Methods: We studied 1921 patients
with rheumatoid arthritis from 8 ARAMIS (Arthritis, Rheumatism, and Ag
ing Medical Information System) centers. Patients were selected for th
e study if they were treated with NSAIDs and had at least 2.5 years of
observation available. Information on GI complications attributed to
NSAIDs was obtained from validated patient self-reports collected ever
y 6 months and supplemented by review of hospital records for all hosp
italizations. Results: Approximately 15% of the 1921 patients reported
an NSAID-induced CI side effect during the 2.5-year observation perio
d. Forty-two patients had a serious GI complication requiring hospital
ization; 34 of these 42 patients did not have a preceding CTI side eff
ect. Patients who were taking antacids and H-2 receptor antagonists di
d not have a significantly lower risk for serious GI complications tha
n did those not taking such medications. Asymptomatic patients taking
these medications had a significantly higher risk for GI complications
compared with those who did not take these medications (standardized
odds ratio, 2.14; 95% confidence interval, 1.06-4.32). Conclusions: A
large majority of patients with serious CI complications do not have p
receding mild side effects. Prophylactic treatment with antacids and H
-2 receptor antagonists is of questionable value and may increase the
risk for subsequent serious GI complications.